ODA will come soon and for rare disease (orphan) designations. A designation from the FDA Committee permits a pharmaceutical company to benefit from incentives to develop a medicine for a rare disease and disorders or a rare cancer. A large number of these diseases affect a small subset of individuals. Once orphan designation is granted a medicine may be developed by a pharmaceutical company.
So you see kiddies for comes the ODA which clears the way for the Pharmy to coma a knocking at Dara's door with a big fat offer. Question is how much would you pay to partner with DARA to further advance the new formulation and ready it for distribution? Remember the patent for the new formulation has already been filed and pending approval, that is pending news in itself. So how much would a big Pharma pay tot co-develop the "only known non opiod product for CIPN" and tap into that $2.5 bil potential market? If history repeats itself the big pharma offer will likely be 10% - 15% of the potential market. which translates to $250 plus million, with the liklihood of 10% - 20% of that as an upfront payment or $25 - $50 million with additional milestone payments. All IMO...GLTA....Point is pending news for ODA, Partnership and Patents will keep the SP running up into earnings. Shaping up to be a hell of a month for March...Cha Ching.
"tap into that $2.5 bil potential market"
Awesome. How did you calculate that? I do recall seeing that on Dara's website, but it is not there anymore. Maybe the figure was for larger CIPN market. So how big is the market for CCIPN orphan drug that targets less than 200,000 people?